Analysen von Michael Leuchten

27.11.17 GSK buy UBS AG
09.11.17 Merck buy UBS AG
03.11.17 Bayer buy UBS AG
01.11.17 Novo Nordisk buy UBS AG
30.10.17 Novartis Neutral UBS AG
27.10.17 Bayer buy UBS AG
26.10.17 GSK Neutral UBS AG
17.10.17 Novo Nordisk buy UBS AG
10.10.17 GSK Neutral UBS AG
29.09.17 Merck buy UBS AG
26.09.17 Merck buy UBS AG
13.09.17 Bayer buy UBS AG
28.08.17 Novartis Neutral UBS AG
24.08.17 Bayer buy UBS AG
23.08.17 Bayer buy UBS AG
17.08.17 Novo Nordisk buy UBS AG
10.08.17 Novo Nordisk buy UBS AG
01.08.17 Novo Nordisk buy UBS AG
01.08.17 GSK Neutral UBS AG
27.07.17 GSK Neutral UBS AG
27.07.17 Bayer buy UBS AG
26.07.17 GSK Neutral UBS AG
26.07.17 Novo Nordisk buy UBS AG
20.07.17 Novartis Neutral UBS AG
18.07.17 Novartis Neutral UBS AG
04.07.17 Bayer buy UBS AG
03.07.17 Bayer buy UBS AG
27.06.17 Bayer buy UBS AG
12.06.17 Novo Nordisk buy UBS AG
09.06.17 GSK Neutral UBS AG
07.06.17 Bayer buy UBS AG
24.05.17 Novartis Neutral UBS AG
15.05.17 GSK Neutral UBS AG
12.05.17 Bayer buy UBS AG
04.05.17 Novo Nordisk buy UBS AG
03.05.17 Novo Nordisk buy UBS AG
28.04.17 Novo Nordisk buy UBS AG
27.04.17 GSK Neutral UBS AG
21.04.17 Novartis Neutral UBS AG
06.04.17 Novartis Neutral UBS AG
14.03.17 Novartis Neutral UBS AG
09.03.17 Novo Nordisk buy UBS AG
08.03.17 GSK Neutral UBS AG
16.02.17 Novo Nordisk buy UBS AG
14.02.17 GSK Neutral UBS AG
03.02.17 Novo Nordisk buy UBS AG
19.01.17 Novo Nordisk buy UBS AG
15.12.16 Bayer buy UBS AG
13.12.16 GSK Neutral UBS AG
08.12.16 Novartis Neutral UBS AG